MGLL and depressive disorder: Activation of cannabinoid receptors using selective agonists as well as indirectly by inhibiting the enzymes involved in the degradation of AEA (fatty acid amide hydrolase (FAAH)) and/or 2-AG (monoacylglycerol lipase (MAGL)) leads to antidepressant-like activity in several animal models of depression [26, 30].